✕

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

10 Strong Buy Small Cap Stocks to Invest In

Page 1 of 3

In this article, we will take a look at 10 Strong Buy Small Cap Stocks to Invest In.

Small-cap stocks have entered a more selective phase following a strong first-half surge that collided with increasing borrowing costs and renewed investor preference for AI-linked megacaps. The Russell 2000 rose about 22% in the first half of 2026, its best start since 1991, before entering correction territory in mid-October, closing 11% lower than its August 14 record close. The pullback was obvious across the market, with Insider Monkey’s coverage of the biggest gainers and losers on October 15 showing the abrupt shift away from riskier sections of the market. The slide hasn’t erased the year’s gains, but it has pushed investors to decide between companies with long-term earnings strength and those that are simply riding the broader small-cap rally.

The fundamental backdrop remains more supportive than recent price action might suggest. Russell 2000 earnings per share increased roughly 43% in the second quarter, well ahead of projections near 26%, while roughly two-thirds of companies exceeded both revenue and earnings estimates. Janus Henderson forecasts small-cap earnings to climb 21.8% in 2027, outpacing its 10.6% estimate for large caps, while adding that the Russell 2000’s relative forward valuation remains historically attractive even after the gap with large caps narrowed.

This combination of robust earnings growth and a still-attractive relative valuation is driving investors back to smaller companies. However, increased long-term Treasury yields remain the key concern. Small caps tend to have more floating-rate or shorter-duration debt than mega-caps, and their valuations are more heavily based on earnings expected further in the future. When the 10-year Treasury yield rises, that future cash flow is discounted more heavily, reducing multiples even when operating results improve.

Royce Investment Partners said the third quarter was a temporary setback after a stellar run, though adding that the climate remains favorable for high-quality small- and micro-cap companies with strong fundamentals. The firm’s Q3 2026 Small Cap Fund letter noted that both the Russell 2000 and Russell Microcap indexes declined 7.2% during the quarter, showing how quickly opinion can shift even while company-level value stays intact.

Longleaf Partners took a similar stance in its Q3 2026 Small-Cap Fund letter, highlighting that concentrated portfolios and company-specific catalysts are more important than broad index exposure in a market where valuations and sentiment can fluctuate sharply.

For investors, that makes analyst conviction useful but insufficient. A Strong Buy rating can reveal companies where Wall Street expects meaningful upside, but small-cap coverage is thinner, projections are erratic, and a single earnings report, financing announcement, or customer loss can have a major impact. The better strategy is to combine analyst support with evidence of revenue growth, margin expansion, cash production, and a balance sheet that can withstand a higher rate environment. Investors should therefore discern between companies with a plausible route to profitability and those whose valuations are based on distant, unproven growth. That distinction is especially important in the current market, with our recent piece titled “13 Best Low Priced Growth Stocks to Invest In Right Now” highlighting why some firms are favoring small caps.

Our Methodology

We used screeners to identify stocks that are trading between $300 and $2 billion and boast a consensus ‘Strong Buy’ rating among analysts. We have also mentioned hedge fund ownership numbers for Q2 2026 to provide insight into smart money sentiments around each stock. The list is arranged according to analyst upside, with each stock carrying a minimum upside potential of 25%, signaling bullish sentiment among Wall Street analysts.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).

10. Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Share Price as of October 23: $10.20

Analyst Upside: 27.45%

Target Price: $13.00

Number of Hedge Fund Holders: 35

Xeris Biopharma Holdings, Inc. markets three specialty drugs: Recorlev for endogenous Cushing’s syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis. Second-quarter revenue increased by 29% to $92.1 million, with net product revenue up 34% and Recorlev up 81% to $56.8 million. Gross margin improved to 86% from 82% a year ago. Management adjusted full-year revenue expectations to $385 million to $390 million, implying more than 30% increase, and expects the larger Recorlev sales team to contribute more in the second half. The Phase 3 study of XP-8121 for hypothyroidism is expected to begin at the end of the year.

The costs of the expansion are obvious. Selling and administrative expenses reached $61 million in the quarter, and management expects full-year spending to increase by around $50 million from 2025. Gvoke had a sluggish start to the year before rising 8% sequentially, and numerous insiders have sold shares in recent weeks. Xeris has been working to expand the protection for its Keveyis franchise. See how that could contribute to long-term growth.

9. Astrana Health, Inc. (NASDAQ:ASTH)

Share Price as of October 23: $37.45

Analyst Upside: 39.92%

Target Price: $52.40

Number of Hedge Fund Holders: 18

Astrana Health, Inc. operates a physician-led, technology-enabled platform that assumes financial risk for patient populations through value-based contracts. The Prospect Health acquisition helped drive a 49% increase in second-quarter revenue to $972.5 million. Adjusted EBITDA increased by 43% to $68.9 million, with adjusted EPS reaching a record $0.80. Full-risk arrangements accounted for 81% of capitation revenue, up from 76% in 2025 and 35% in 2022, while general and administrative costs decreased to 5.6% of revenue from 7.7%. Management reiterated projections for revenue of $3.8 billion to $4.1 billion and raised adjusted EBITDA guidance to $255 million to $280 million from $205.4 million in 2025. First-half free cash flow of $92.9 million reduced net leverage to 2.26 times adjusted EBITDA.

Valuation remains a key aspect of the bull case. Astrana is trading at 18.91x forward earnings, a meaningful discount to its trailing P/E of 45.70x. That disparity indicates that the market is pricing in significant earnings growth as the company absorbs Prospect Health, extends full-risk arrangements, and translates scale into operating leverage.

That said, the model involves volatility. Taking full risk implies that medical costs can quickly erode margins, and second-quarter revenue reflected a one-time $15 million reduction due to CMS adjustments for the ACO REACH program. Earlier in May, Barclays raised the shares to Overweight with a $50 price target, citing an improved outlook for value-based care. Read why Barclays turned optimistic.

Page 1 of 3